Effect of Statins on Skeletal Muscle Function

Background— Many clinicians believe that statins cause muscle pain, but this has not been observed in clinical trials, and the effect of statins on muscle performance has not been carefully studied. Methods and Results— The Effect of Statins on Skeletal Muscle Function and Performance (STOMP) study assessed symptoms and measured creatine kinase, exercise capacity, and muscle strength before and after atorvastatin 80 mg or placebo was administered for 6 months to 420 healthy, statin-naive subjects. No individual creatine kinase value exceeded 10 times normal, but average creatine kinase increased 20.8±141.1 U/L (P<0.0001) with atorvastatin. There were no significant changes in several measures of muscle strength or exercise capacity with atorvastatin, but more atorvastatin than placebo subjects developed myalgia (19 versus 10; P=0.05). Myalgic subjects on atorvastatin or placebo had decreased muscle strength in 5 of 14 and 4 of 14 variables, respectively (P=0.69). Conclusions— These results indicate that high-dose atorvastatin for 6 months does not decrease average muscle strength or exercise performance in healthy, previously untreated subjects. Nevertheless, this blinded, controlled trial confirms the undocumented impression that statins increase muscle complaints. Atorvastatin also increased average creatine kinase, suggesting that statins produce mild muscle injury even among asymptomatic subjects. This increase in creatine kinase should prompt studies examining the effects of more prolonged, high-dose statin treatment on muscular performance. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00609063.

[1]  Cecil R. Reynolds,et al.  Physicians' Desk Reference , 2014 .

[2]  P. Thompson,et al.  Effect of statins on creatine kinase levels before and after a marathon run. , 2012, The American journal of cardiology.

[3]  J. Breslow,et al.  Needed: pragmatic clinical trials for statin-intolerant patients. , 2011, The New England journal of medicine.

[4]  Y. Khader,et al.  Prevalence and risk factors of muscle complications secondary to statins , 2011, Muscle & nerve.

[5]  S. Krähenbühl,et al.  Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. , 2011, Biochimica et biophysica acta.

[6]  H. Runnels,et al.  Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. , 2011, The American journal of pathology.

[7]  L. Ngo,et al.  Evaluation of skeletal muscle during calf exercise by 31‐phosphorus magnetic resonance spectroscopy in patients on statin medications , 2011, Muscle & nerve.

[8]  P. Thompson,et al.  The effects of statins on skeletal muscle strength and exercise performance , 2010, Current opinion in lipidology.

[9]  E. Hoffman,et al.  A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. , 2010, Preventive cardiology.

[10]  B. Golomb,et al.  Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients , 2010, Pharmacotherapy.

[11]  Hans Hoppeler,et al.  Association between statin-associated myopathy and skeletal muscle damage , 2009, Canadian Medical Association Journal.

[12]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[13]  Andrea Gaggioli,et al.  Neurorehabil Neural Repair , 2008 .

[14]  Michiaki Yamashita,et al.  The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. , 2007, The Journal of clinical investigation.

[15]  R. Haas,et al.  Observations from a statin myopathy clinic. , 2006, Archives of internal medicine.

[16]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[17]  E. Hoffman,et al.  Changes in Ubiquitin Proteasome Pathway Gene Expression in Skeletal Muscle With Exercise and Statins , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[18]  B. Dobkin Underappreciated Statin-Induced Myopathic Weakness Causes Disability , 2005, Neurorehabilitation and neural repair.

[19]  A. Kriska,et al.  Skeletal muscle fatigue, strength, and quality in the elderly: the Health ABC Study. , 2005, Journal of applied physiology.

[20]  R. Naviaux,et al.  Statin myotoxicity is associated with changes in the cardiopulmonary function. , 2004, Atherosclerosis.

[21]  L. Teichholz Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.

[22]  S. Grundy,et al.  ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. , 2002, Circulation.

[23]  Jennie Chang,et al.  Cerivastatin and reports of fatal rhabdomyolysis. , 2002, The New England journal of medicine.

[24]  I. Hamilton-Craig,et al.  Statin‐associated myopathy , 2001, The Medical journal of Australia.

[25]  M. Barbagallo,et al.  Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. , 2000, Atherosclerosis.

[26]  Y. H. Lee,et al.  Serum Creatine Kinase in Patients with Rheumatic Diseases , 2000, Clinical Rheumatology.